Shareholders Equity (Quarterly) Chart

View Shareholders Equity (Quarterly) for IGC.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Shareholders Equity (Quarterly) Chart
Start Trial

Historical Shareholders Equity (Quarterly) Data

View and export this data back to 2005. Start Trial.
Date Value
June 30, 2026 6.132M
March 31, 2026 6.121M
December 31, 2025 7.423M
September 30, 2025 8.092M
June 30, 2025 6.078M
March 31, 2025 6.33M
December 31, 2024
September 30, 2024 7.377M
June 30, 2024 7.88M
March 31, 2024 7.321M
December 31, 2023 9.053M
September 30, 2023 14.10M
June 30, 2023 13.20M
March 31, 2023 14.91M
December 31, 2022 18.32M
September 30, 2022 20.14M
June 30, 2022 22.04M
March 31, 2022 23.89M
December 31, 2021 29.48M
September 30, 2021 31.26M
June 30, 2021 31.74M
March 31, 2021 32.80M
December 31, 2020 21.47M
September 30, 2020 23.60M
June 30, 2020 24.86M
Date Value
March 31, 2020 26.54M
December 31, 2019 29.79M
September 30, 2019 31.24M
June 30, 2019 32.42M
March 31, 2019 33.57M
December 31, 2018 36.56M
September 30, 2018 13.81M
June 30, 2018 7.577M
March 31, 2018 8.065M
December 31, 2017 7.484M
September 30, 2017 6.230M
June 30, 2017 6.104M
March 31, 2017 7.359M
December 31, 2016 7.549M
September 30, 2016 14.40M
June 30, 2016 13.10M
March 31, 2016 13.48M
December 31, 2015 13.09M
September 30, 2015 13.57M
June 30, 2015 13.98M
March 31, 2015 14.23M
December 31, 2014 15.74M
September 30, 2014 15.36M
June 30, 2014 16.25M
March 31, 2014 13.63M

Shareholders' Equity Definition

Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.

Read full definition.

Shareholders Equity (Quarterly) Range, Past 5 Years

View Shareholders Equity (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Shareholders Equity (Quarterly) Benchmarks

View Shareholders Equity (Quarterly) Benchmarks
Start Trial
Cocrystal Pharma, Inc. 1.044M
CNBX Pharmaceuticals, Inc. -2.660M
GB Sciences, Inc. --
Arvinas, Inc. 562.20M
Fulcrum Therapeutics, Inc. 310.70M

Shareholders Equity (Quarterly) Related Metrics